Brokers Issue Forecasts for ZNTL FY2030 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Zentalis Pharmaceuticals in a report released on Friday, March 27th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.06) for the year. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share.

ZNTL has been the subject of a number of other reports. Wells Fargo & Company started coverage on shares of Zentalis Pharmaceuticals in a research report on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 price target for the company. Guggenheim reissued a “buy” rating and issued a $6.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday. Finally, Wall Street Zen cut Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Zentalis Pharmaceuticals presently has an average rating of “Hold” and an average target price of $5.17.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $2.10 on Monday. The company’s fifty day simple moving average is $2.57 and its 200-day simple moving average is $1.95. Zentalis Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $3.95. The company has a market cap of $148.95 million, a PE ratio of -1.11 and a beta of 1.71.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.08).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. 5AM Venture Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 705.7% in the 4th quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after acquiring an additional 3,457,913 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter valued at approximately $27,000. GSA Capital Partners LLP lifted its stake in Zentalis Pharmaceuticals by 8.5% during the fourth quarter. GSA Capital Partners LLP now owns 1,169,573 shares of the company’s stock worth $1,579,000 after purchasing an additional 91,917 shares during the last quarter. Barr E S & Co. lifted its stake in Zentalis Pharmaceuticals by 43.8% during the fourth quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock worth $78,000 after purchasing an additional 17,500 shares during the last quarter. Finally, 49 Wealth Management LLC boosted its holdings in Zentalis Pharmaceuticals by 151.5% in the fourth quarter. 49 Wealth Management LLC now owns 70,911 shares of the company’s stock worth $96,000 after purchasing an additional 42,719 shares during the period.

Insider Transactions at Zentalis Pharmaceuticals

In related news, major shareholder Group Walters purchased 6,459,973 shares of Zentalis Pharmaceuticals stock in a transaction dated Wednesday, December 31st. The shares were acquired at an average price of $1.20 per share, with a total value of $7,751,967.60. Following the completion of the transaction, the insider owned 13,509,973 shares of the company’s stock, valued at approximately $16,211,967.60. This trade represents a 91.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Vincent Vultaggio sold 29,951 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the transaction, the insider owned 156,779 shares of the company’s stock, valued at $380,972.97. This trade represents a 16.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 46,617 shares of company stock worth $113,417. Company insiders own 1.90% of the company’s stock.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.